Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

Opens in a new tab or window A biomarker test identified tau pathology in Alzheimer's disease before fibrillary tangles developed. Neurofibrillary tangle formation can be prevented by targeting ...

The study used gold-standard autopsy confirmation to show that a blood test for Alzheimer's disease accurately detected ...

The sabotage of cellular messaging, triggered by the formation of chronic stress granules in the brain, may be a key factor ...

Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

Researchers say CSF biomarker test correlates with the severity of cognitive decline, independent of other factors, including brain amyloid deposition.

The test could help identify one key Alzheimer's biomarker, tau protein, before it shows up in brain. Here's what experts say ...

The project specifically focused on the hippocampus, a region of the brain that's not only crucial for memory but also ...

Jan. 15, 2025 — Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a ...

Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...